Physician profile
Kelley D Smith
NPI 1396796637
$584.80
in general payments reported to CMS, 2019-2025
12 companies · $113 in 2025
The $113 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.24 · 2020: $15.29 · 2021: $73.77 · 2022: $51.38 · 2023: $24.76 · 2024: $217 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $354.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $148.17 | 2021-2024 | Xolair |
| Pfizer INC. | $77.30 | 2024-2025 | |
| Cranial Technologies, INC | $73.22 | 2019-2021 | |
| Sanofi Pasteur INC. | $59.34 | 2022-2025 | |
| Glaxosmithkline, LLC. | $54.78 | 2019-2024 | Bexsero |
| Sanofi-Aventis U.S. LLC | $48.38 | 2024-2025 | |
| Stryker Corporation | $34.68 | 2022 | |
| Organon LLC | $24.76 | 2023 | Nexplanon |
| Adlon Therapeutics L.P. | $21.09 | 2019 | |
| Supernus Pharmaceuticals, INC. | $17.28 | 2021 | |
| Merck Sharp & Dohme LLC | $13.89 | 2025 | Varivax, Proquad, M-M-R II |
| Kaleo, INC. | $11.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelley Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.